Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma

被引:0
|
作者
Opalinska, Marta [2 ]
Sowa-Staszczak, Anna [1 ]
Al Maraih, Ibraheem [2 ]
Gilis-Januszewska, Aleksandra [3 ]
Hubalewska-Dydejczyk, Alicja [3 ]
机构
[1] Jagiellonian Univ, Dept Endocrinol, Med Coll, Ul Sw Anny 12, PL-31501 Krakow, Poland
[2] Univ Hosp, Dept Endocrinol Oncol Endocrinol & Nucl Med, Nucl Med Unit, Krakow, Poland
[3] Jagiellonian Univ, Chair & Dept Endocrinol, Med Coll, Krakow, Poland
关键词
diazoxide; hypoglycemia; insulinoma; NET; neuroendocrine tumors; PRRT; PANCREATIC NEUROENDOCRINE TUMORS; SURGICAL-TREATMENT; GUIDELINES; DIAGNOSIS;
D O I
10.1515/bams-2021-0138
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: Severe hypoglycemia in a course of inoperable insulinoma may be life-threating and often it is not well controlled, even by high doses of diazoxide requiring second line treatment. Among available methods PRRT is characterized by relatively low toxicity and is connected with favorable antitumor effect. The aim of the study was an evaluation of the PRRT effectiveness in control of hypoglycemia in patients with primary inoperable insulinoma. Methods: Three patients (female with metastatic insulinoma, male with primary inoperable pancreatic tumor, female with MEN1 syndrome and hepatic metastases) were treated with PRRT due to severe hypoglycemia poorly controlled by diazoxide in course of primary inoperable insulinoma. Results: Patient 1 baseline fasting glucose concentration increased from 2.4 mmol/L [3.30-5.60] to 5.9 mmol/L after PRRT. In patient 2 fasting glucose level 2.30 mmol/L increased after PRRT to 7.0 mmol/L, while baseline insulin level initially 31.15 uU/mL [2.6-24.9] decreased to 15.4 uU/mL. In patients 3, baseline fasting glucose level 2.5 mmol/L increased after PRRT to 7.9 mmol/L, and insulin decreased from 57.9 uU/mL to 6.3 uU/mL. In imaging there was partial response (PR) in patient 1 and 2 and stabilization of the tumor size in patient 3. In patient 2 reduction of tumor infiltration let for curative surgery performed 4 months after PPRT. Conclusions: PRRT may be effective as a first or second line treatment in management of hypoglycemia for patients with hormonally active inoperable insulinoma.
引用
收藏
页码:221 / 226
页数:6
相关论文
共 50 条
  • [1] Metastatic Insulinoma With Refractory Hypoglycemia With Complete Response to Peptide Receptor Radionuclide Therapy
    Duarte, Diana Borges
    Elvas, Ana Rita
    Couto, Joana
    Domingues, Isabel
    Oliveira, Sofia
    Martins, Raquel G.
    [J]. PANCREAS, 2022, 51 (09) : E110 - E112
  • [2] Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy
    van Schaik, E.
    van Vliet, E. I.
    Feelders, R. A.
    Krenning, E. P.
    Khan, S.
    Kamp, K.
    Valkema, R.
    van Nederveen, F. H.
    Teunissen, J. J. M.
    Kwekkeboom, D. J.
    de Herder, W. W.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (11): : 3381 - 3389
  • [3] Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
    Sowa-Staszczak, Anna
    Pach, Dorota
    Chrzan, Robert
    Trofimiuk, Malgorzata
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Kolodziej, Maciej
    Mikolajczak, Renata
    Pawlak, Dariusz
    Hubalewska-Dydejczyk, Alicja
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (09) : 1669 - 1674
  • [4] Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
    Anna Sowa-Staszczak
    Dorota Pach
    Robert Chrzan
    Małgorzata Trofimiuk
    Agnieszka Stefańska
    Monika Tomaszuk
    Maciej Kołodziej
    Renata Mikołajczak
    Dariusz Pawlak
    Alicja Hubalewska-Dydejczyk
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38
  • [5] Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
    Opalinska, Marta
    Sowa-Staszczak, Anna
    Grochowska, Anna
    Olearska, Helena
    Hubalewska-Dydejczyk, Alicja
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] TREATMENT OF SEVERE HYPOGLYCEMIA IN INOPERABLE INSULINOMA WITH THE SOMATOSTATIN ANALOG SMS-201-995
    DIEM, P
    PEYER, T
    KOECHLI, HP
    SCHAEDELIN, J
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1987, : 17 - 17
  • [7] Peptide Receptor Radionuclide Therapy in Patients with Inoperable Meningiomas: Our Experience and Review of the Literature
    Minutoli, Fabio
    Amato, Ernesto
    Sindoni, Alessandro
    Cardile, Davide
    Conti, Alfredo
    Herberg, Astrid
    Baldari, Sergio
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2014, 29 (05) : 193 - 199
  • [8] Neoadjuvant Peptide Receptor Radionuclide Therapy for an Inoperable Neuroendocrine Pancreatic Carcinoma
    Kaemmerer, D.
    Prasad, V
    Daffner, W.
    Hoersch, D.
    Kloeppel, G.
    Hommann, M.
    Baum, R. P.
    [J]. NEUROENDOCRINOLOGY, 2010, 92 (01) : 35 - 35
  • [9] Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
    Daniel Kaemmerer
    Vikas Prasad
    Wolfgang Daffner
    Dieter Hrsch
    Günter Klppel
    Merten Hommann
    Richard P Baum
    [J]. World Journal of Gastroenterology, 2009, 15 (46) : 5867 - 5870
  • [10] Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
    Kaemmerer, Daniel
    Prasad, Vikas
    Daffner, Wolfgang
    Hoersch, Dieter
    Kloeppel, Guenter
    Hommann, Merten
    Baum, Richard P.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (46) : 5867 - 5870